{
    "code": "52026742",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52026742",
    "time": "2024-01-18 19:37:36",
    "許可證字號": "衛部藥輸字第026742號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "115\/10\/14",
    "發證\/登錄日期": "105\/10\/14",
    "許可證\/登錄種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA05202674207",
    "中文品名": "大塚安立復內服液劑",
    "英文品名": "OTSUKA ABILIFY Oral Solution",
    "適應症": "1.成人和青少年(13至17歲)的思覺失調症。 \r\n2.成人和兒童(10至17歲)的雙極性疾患之躁症發作及混合型發作，可單獨使用或做為鋰鹽或Valproate的輔助治療。 \r\n3.第一型雙極性疾患維持治療之鋰鹽或valproate的輔助治療。 \r\n4.重鬱症之輔助治療。 \r\n5.兒童(6至17歲)的自閉性疾患伴隨之急躁易怒。\r\n6.妥瑞氏症。",
    "劑型": "170內服液劑",
    "包裝": "4~4000毫升以下PET塑膠瓶裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "ARIPIPRAZOLE",
    "限制項目": "02輸　入 26監視期滿新藥",
    "申請商名稱": "台灣大塚製藥股份有限公司",
    "申請商地址": "台北市中山區復興北路378號11樓",
    "主製造廠": [
        {
            "製造廠名稱": "KOREA OTSUKA PHARMACEUTICAL CO., LTD.",
            "製造廠廠址": "27, JEYAKGONGDAN 3-GIL, HYANGNAM-EUP, HWASEONG-SI, GYEONGGI-DO, 18622, KOREA",
            "製造廠公司地址": "",
            "製造廠國別": "KOREA",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "台灣大塚製藥股份有限公司中壢工廠",
            "製造廠廠址": "桃園市中壢區吉林路１５號",
            "製造廠公司地址": "",
            "製造廠國別": "TAIWAN",
            "製程": "包裝"
        },
        {
            "製造廠名稱": "KOREA OTSUKA PHARMACEUTICAL CO., LTD.",
            "製造廠廠址": "OTSUKA VISION BLDG., 226, YEOKSAM-RO, GANGNAM-GU, SEOUL 06227, KOREA",
            "製造廠公司地址": "",
            "製造廠國別": "KOREA",
            "製程": "公司"
        }
    ],
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200095400",
            "成分名稱": "ARIPIPRAZOLE",
            "含量描述": "",
            "含量": "1.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "26228_3. 大塚安立復內服液劑_PI_20200622-109-07-08.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026742&Seq=003&Type=9"
        },
        {
            "title": "Abilify OS_label _final-106-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026742&Seq=002&Type=8"
        },
        {
            "title": "Abilify OS_carton _final-106-03-21.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026742&Seq=001&Type=8"
        }
    ]
}